Melanie Greenland
MSc BSc
Medical Statistician
Melanie is a Medical Statistician at the Oxford Vaccine Group with experience of clinical trials in vaccinology, women's reproductive health, obstetrics and neonatal research. She also has experience in epidemiology in cardiovascular research using linked electronic health data and Biobank data. She holds a BSc in Mathematics and MSc in Biometry. She joined the team in 2020 and is currently involved in COVID, typhoid fever and pregnancy vaccine trials.
Recent publications
-
Towards better reporting of the Proportion of Days Covered method in cardiovascular medication adherence: A scoping review and new tool TEN-SPIDERS.
Journal article
Dalli LL. et al, (2022), Br J Clin Pharmacol
-
Two-year follow-up of infant and maternal outcomes after planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial.
Journal article
Beardmore-Gray A. et al, (2022), BJOG
-
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Journal article
Stuart ASV. et al, (2021), Lancet
-
Greater Adherence to Secondary Prevention Medications Improves Survival After Stroke or Transient Ischemic Attack: A Linked Registry Study.
Journal article
Dalli LL. et al, (2021), Stroke, 52, 3569 - 3577
-
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Journal article
Liu X. et al, (2021), Lancet, 398, 856 - 869